Table 3.
Examples of clinical trials on drugs related to Cu. Information was obtained from the public database (http://www.clinicaltrials.gov/), accessed on 11 November 2023.
| Disease | Trial Phase | Intervention | Trial ID | Status | Study Completion |
|---|---|---|---|---|---|
| Breast Cancer | Phase 2 | TM | NCT00195091 | Active, not recruiting |
06/2025 |
| Wilson’s Disease | Phase 2 | ALXN1840 | NCT04422431 | Completed | 05/2023 |
| EOC, TC, PPC | Phase 1–2 | Trientine 2HC + PLD + carboplatin |
NCT03480750 | Completed | 12/2019 |
| Advanced cancers | Phase 1 | Trientine 4HC + carboplatin |
NCT01178112 | Completed | 08/2014 |
| EOC, TC, PPC | Phase 2 | Elesclomol + paclitaxel | NCT00888615 | Completed | 08/2016 |
| CC | Phase 2 | 64CuII(atsm) | NCT00794339 | Terminated | 12/2011 |
| CIN | Phase 2 | Curcumin | NCT04266275 | Not yet recruiting |
03/2025 |
| CC | Phase 1–2 | Curcumin + radiotherapy |
NCT05947513 | Not yet recruiting |
11/2024 |
| CC | Phase 2 | Curcumin | NCT04294836 | Withdrawn | 12/2023 |
| EDT | Phase 2 | Curcumin | NCT04493476 | Unknown Status |
12/2022 |
| CC, EC | Phase 2 | Pembrolizumab + radiation + curcumin + immune modulatory cocktail |
NCT03192059 | Completed | 06/2021 |
| EC | Phase 2 | Curcumin | NCT02017353 | Completed | 10/2016 |